Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KC-4465

293T-GARP-Cell-Line

Home » 293T-GARP-Cell-Line

Background of 293T-GARP-Cell-Line

GARP, also known as LRRC32, is a type I transmembrane cell surface docking receptor that mediates the high expression of potential transforming growth factor beta (TGF - β) on regulatory T lymphocytes and platelets. It is a transmembrane protein highly expressed by activated Tregs and plays a key role in the activation of TGF - β, thereby promoting the immunosuppressive effect of Tregs. The overexpression of GARP in human cancers is associated with tolerance to TME and adverse clinical reactions to ICB, indicating that GARP blockade may improve cancer immunotherapy.

Specifications

Catalog Number:
KC-4465
Cell Line Name:
293T-GARP-Cell-Line
Clone Number
Host Cell Line:
293T
Description:
Stable 293T clone expressing exogenous GARP gene
Quantity:
Two vials of frozen cells (2-5×106/vial)
Stability:
Stable in culture over a minimum of 10 passages
Application:
Drug screening and biological assays
Freezing Medium:
70% DMEM + 20% FBS + 10% DMSO
Propagation Medium:
DMEM + 10% FBS + 1μg/mL Puromycin
Selection Marker:
Puromycin
Morphology:
Epithelial
Subculture:
Split saturated culture 1:4-1:8 every 2-3 days; seed out at about 1-3 × 105 cells/mL
Incubation:
37 °C with 5% CO2
Storage:
Liquid nitrogen immediately upon receiving
Doubling Time:
Approximately 30 hours
Mycoplasma Status:
Negative
In Vivo Validation:

Cell Line Generation

293T-GARP-cell-line was generated using a lentiviral vector expressing the GARP sequence.

Characterization

Figure 1: Characterization of GARP overexpression in the 293T-GARP stable clone using FACS.

Figure 2: Characterization of GARP in the 293T-GARP stable clone using PCR sequencing.

Cell Resuscitation

  1. Prewarm culture medium (DMEM supplemented with 10% FBS and 1μg/mL puromycin)in a 37°C water bath.
  2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
  3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
  4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium.
  5. Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
  6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
  7. Incubate the flask at 37°C, 5% CO2 incubator.
  8. Split saturated culture 1:4-1:8 every 2-3 days; seed out at about 1-3 × 105 cells/mL.

Cell Freezing

  1. Prepare the freezing medium (70% DMEM + 20% FBS + 10% DMSO) fresh immediately before use.
  2. Keep the freezing medium on ice and label cryovials.
  3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature and carefully aspirate off the medium.
  5. Resuspend the cells at a density of at least 3×106 cells/mL in chilled freezing medium.
  6. Aliquot 1 mL of the cell suspension into each cryovial.
  7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.
  8. Transfer vials to liquid nitrogen for long-term storage.

References

  1. Bellaye PS, Dias AM, Vrigneaud JM, Bouchard A, Moreau M, Petitot C, Bernhard C, Claron M, Froidurot L, Morgand V, Guillemin M, Monterrat M, Mirjolet C, Garrido C, Kohli E, Collin B. Targeted radionuclide therapy against GARP expressing T regulatory cells after tumour priming with external beam radiotherapy in a murine syngeneic model. Heliyon. 2024 Oct 18;10(20):e39543. doi: 10.1016/j.heliyon.2024.e39543. PMID: 39498075; PMCID: PMC11533616.
  2. Li A, Chang Y, Song NJ, Wu X, Chung D, Riesenberg BP, Velegraki M, Giuliani GD, Das K, Okimoto T, Kwon H, Chakravarthy KB, Bolyard C, Wang Y, He K, Gatti-Mays M, Das J, Yang Y, Gewirth DT, Ma Q, Carbone D, Li Z. Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8+ T cell antitumor immunity. J Immunother Cancer. 2022 Sep;10(9):e005433. doi: 10.1136/jitc-2022-005433. PMID: 36096533; PMCID: PMC9472209.